Endo CEO Rajiv De Silva steps down, replaced by former Par CEO
Mr. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical.
Mr. Campanelli joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as Chief Executive Officer since 2012. Since joining Endo, he has overseen the Company's U.S. Generic Pharmaceuticals business.
Prior to becoming CEO of Par in 2012, Mr. Campanelli served as Chief Operating Officer of Par Pharmaceutical. Previously, he held roles of increasing responsibility at Par, including President, Par Generics, and Executive Vice President, Business Development & Licensing for branded and generic products.
He has more than 25 years of experience in the generics and branded pharmaceutical industry.
Mr. Campanelli, who will also join Endo's Board of Directors, succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.